Cancer Gene Therapy Market: by Therapy Type (Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer), End-User (Hospitals and Clinics, Biopharma and Biotechnology Companies, Academic and Research Institutes, Others), and by Geography

 

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Cancer gene therapy market size was valued at USD 629 million in the year 2021 and is anticipated to reach 3351.79 million at a CAGR of 27% by 2028 during the forecast period 2022-2028. Cancer gene therapy is a process that treats cancers by inserting therapeutic DNA into the patient. Cancer gene therapy is gaining popularity as a result of its success rate in preclinical and clinical trial stages. The most common technique for cancer gene therapy involves replacing a mutated gene that is causing cancer with a healthy copy of the gene. A new technique that is being introduced to cancer gene therapy market involves insertion of new genes into the body that would help to fight against tumor cells. In July 2017, Novartis received U.S. FDA Oncologic Drugs Advisory Committee (ODAC) recommended approval of CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia.In June 2017, Cell Medica acquired the Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult’s GMP manufacturing facility in Stevenage, UK. In June 2013, BioSante Pharmaceuticals, Inc. completed the merger of its wholly-owned subsidiary with and into ANIP Acquisition Company, ANI Pharmaceuticals, Inc.

Cancer gene therapy market report gives comprehensive outlook on global market scenario, growth trends, shares, with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The report on cancer gene therapy market gives historical, current, and future market sizes (US$ Mn) on the basis of type, therapy, end-user, and region. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyze the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include manufacturers, distributors, policy makers, and service providers engaged in cancer gene therapy

Global Cancer Gene Therapy Market Summary

Study Period

2023-29

Base Year

2022

CAGR

27%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Cancer Gene Therapy Market Dynamics

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. Various factors, such as the increase in the prevalence of cancer, rising government initiatives, increase in funding from various government and non-government organizations, ethical acceptance of gene therapy for treatment of diseases and growing popularity of DNA vaccines is driving the global cancer gene therapy market. However, less awareness and high cost involved in treatment, Lack of reimbursement policies for advanced gene therapy methods are restraining the growth of the global market for cancer gene therapy.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Cancer Gene Therapy Market Segmentation

Type Therapy Type
  • Gene Induced Immunotherapy
  • Oncolytic Virotherapy
  • Gene Transfer
End-User
  • Hospitals and Clinic
  • Biopharma and Biotechnology Companies
  • Academic and Research Institutes
  • Others
Geography
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

1. Executive Summary
2. Global Cancer Gene Therapy Market Introduction
2.1. Global Cancer Gene Therapy Market – Taxonomy
2.2. Global Cancer Gene Therapy Market –Definitions
2.2.1. Therapy Type
2.2.2. End User
2.2.3. Region
3. Global Cancer Gene Therapy Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Current Trends
3.5. Global Cancer Gene Therapy Market Dynamic Factors - Impact Analysis
3.6. Mergers, Acquisitions, and Collaborations
4. Global Cancer Gene Therapy Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028
4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Cancer Gene Therapy Market, By Therapy Type, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.1. Gene Induced Immunotherapy
5.1.1. Delivery of Cytokines Gene
5.1.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Delivery of Tumor Antigen Gene
5.1.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.2. Oncolytic Virotherapy
5.2.1. Adenovirus
5.2.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Lentivirus
5.2.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Retro virus
5.2.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
5.2.4. Adeno Associated Virus
5.2.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.4.3. Market Opportunity Analysis
5.2.5. Herpes Simplex Virus
5.2.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.5.3. Market Opportunity Analysis
5.2.6. Alpha Virus
5.2.6.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.6.3. Market Opportunity Analysis
5.2.7. Vaccinia Virus
5.2.7.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.7.3. Market Opportunity Analysis
5.2.8. Simian Virus
5.2.8.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.2.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.8.3. Market Opportunity Analysis
5.2.9. Others
5.2.9.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.2.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.9.3. Market Opportunity Analysis
5.3. Gene Transfer
5.3.1. Naked/Plasmid Vectors
5.3.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.1.3. Market Opportunity Analysis
5.3.2. Electroporation
5.3.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.2.3. Market Opportunity Analysis
5.3.3. Sonoporation
5.3.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3.3. Market Opportunity Analysis
5.3.4. Magnetofection
5.3.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.3.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.4.3. Market Opportunity Analysis
5.3.5. Gene gun
5.3.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.3.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.5.3. Market Opportunity Analysis
6. Global Cancer Gene Therapy Market, By End User, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
6.1. Hospitals and Clinics
6.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Biopharma and Biotechnology Companies
6.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Academic and Research Institutes
6.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Cancer Gene Therapy Market Forecast, By Region, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia Pacific
7.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. MEA
7.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Region, 2022 - 2028
8. North America Cancer Gene Therapy Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
8.1. Therapy Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Gene Induced Immunotherapy
8.1.1.1. Delivery of Cytokines Gene
8.1.1.2. Delivery of Tumor Antigen Gene
8.1.2. Oncolytic Virotherapy
8.1.2.1. Adenovirus
8.1.2.2. Lentivirus
8.1.2.3. Retro virus
8.1.2.4. Adeno Associated Virus
8.1.2.5. Herpes Simplex Virus
8.1.2.6. Alpha Virus
8.1.2.7. Vaccinia Virus
8.1.2.8. Simian Virus
8.1.2.9. Others
8.1.3. Gene Transfer
8.1.3.1. Naked/Plasmid Vectors
8.1.3.2. Electroporation
8.1.3.3. Sonoporation
8.1.3.4. Magnetofection
8.1.3.5. Gene gun
8.2. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Hospitals and Clinics
8.2.2. Biopharma and Biotechnology Companies
8.2.3. Academic and Research Institutes
8.2.4. Others
8.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.3.1. United States
8.3.2. Canada
8.4. North America Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027
8.5. North America Cancer Gene Therapy Market Dynamics – Trends
9. Europe Cancer Gene Therapy Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
9.1. Therapy Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Gene Induced Immunotherapy
9.1.1.1. Delivery of Cytokines Gene
9.1.1.2. Delivery of Tumor Antigen Gene
9.1.2. Oncolytic Virotherapy
9.1.2.1. Adenovirus
9.1.2.2. Lentivirus
9.1.2.3. Retro virus
9.1.2.4. Adeno Associated Virus
9.1.2.5. Herpes Simplex Virus
9.1.2.6. Alpha Virus
9.1.2.7. Vaccinia Virus
9.1.2.8. Simian Virus
9.1.2.9. Others
9.1.3. Gene Transfer
9.1.3.1. Naked/Plasmid Vectors
9.1.3.2. Electroporation
9.1.3.3. Sonoporation
9.1.3.4. Magnetofection
9.1.3.5. Gene gun
9.2. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Hospitals and Clinics
9.2.2. Biopharma and Biotechnology Companies
9.2.3. Academic and Research Institutes
9.2.4. Others
9.3. Country Level Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. UK
9.3.2. Germany
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Europe Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027
9.5. Europe Cancer Gene Therapy Market Dynamics – Trends
10. Asia Pacific Cancer Gene Therapy Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
10.1. Therapy Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Gene Induced Immunotherapy
10.1.1.1. Delivery of Cytokines Gene
10.1.1.2. Delivery of Tumor Antigen Gene
10.1.2. Oncolytic Virotherapy
10.1.2.1. Adenovirus
10.1.2.2. Lentivirus
10.1.2.3. Retro virus
10.1.2.4. Adeno Associated Virus
10.1.2.5. Herpes Simplex Virus
10.1.2.6. Alpha Virus
10.1.2.7. Vaccinia Virus
10.1.2.8. Simian Virus
10.1.2.9. Others
10.1.3. Gene Transfer
10.1.3.1. Naked/Plasmid Vectors
10.1.3.2. Electroporation
10.1.3.3. Sonoporation
10.1.3.4. Magnetofection
10.1.3.5. Gene gun
10.2. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Hospitals and Clinics
10.2.2. Biopharma and Biotechnology Companies
10.2.3. Academic and Research Institutes
10.2.4. Others
10.3. Country Level Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. ANZ
10.3.4. Japan
10.3.5. Rest of APAC
10.4. Asia Pacific Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027
10.5. Asia Pacific Cancer Gene Therapy Market Dynamics – Trends
11. Latin America Cancer Gene Therapy Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
11.1. Therapy Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Gene Induced Immunotherapy
11.1.1.1. Delivery of Cytokines Gene
11.1.1.2. Delivery of Tumor Antigen Gene
11.1.2. Oncolytic Virotherapy
11.1.2.1. Adenovirus
11.1.2.2. Lentivirus
11.1.2.3. Retro virus
11.1.2.4. Adeno Associated Virus
11.1.2.5. Herpes Simplex Virus
11.1.2.6. Alpha Virus
11.1.2.7. Vaccinia Virus
11.1.2.8. Simian Virus
11.1.2.9. Others
11.1.3. Gene Transfer
11.1.3.1. Naked/Plasmid Vectors
11.1.3.2. Electroporation
11.1.3.3. Sonoporation
11.1.3.4. Magnetofection
11.1.3.5. Gene gun
11.2. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Hospitals and Clinics
11.2.2. Biopharma and Biotechnology Companies
11.2.3. Academic and Research Institutes
11.2.4. Others
11.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of LA
11.4. Latin America Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027
11.5. Latin America Cancer Gene Therapy Market Dynamics – Trends
12. MEA Cancer Gene Therapy Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
12.1. Therapy Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Gene Induced Immunotherapy
12.1.1.1. Delivery of Cytokines Gene
12.1.1.2. Delivery of Tumor Antigen Gene
12.1.2. Oncolytic Virotherapy
12.1.2.1. Adenovirus
12.1.2.2. Lentivirus
12.1.2.3. Retro virus
12.1.2.4. Adeno Associated Virus
12.1.2.5. Herpes Simplex Virus
12.1.2.6. Alpha Virus
12.1.2.7. Vaccinia Virus
12.1.2.8. Simian Virus
12.1.2.9. Others
12.1.3. Gene Transfer
12.1.3.1. Naked/Plasmid Vectors
12.1.3.2. Electroporation
12.1.3.3. Sonoporation
12.1.3.4. Magnetofection
12.1.3.5. Gene gun
12.2. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Hospitals and Clinics
12.2.2. Biopharma and Biotechnology Companies
12.2.3. Academic and Research Institutes
12.2.4. Others
12.3. Country Level Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. GCC Countries
12.3.2. South Africa
12.3.3. Rest of MEA
12.4. MEA Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027
12.5. MEA Cancer Gene Therapy Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Urigen Pharmaceuticals Inc.
13.2.2. GenVec.Inc
13.2.3. Oxford BioMedica
13.2.4. Vical
13.2.5. ANI Pharmaceuticals, Inc.
13.2.6. Genzyme Corporation
13.2.7. Novartis AG
13.2.8. Cell Medica
13.2.9. Cell Genesys Inc.
13.2.10. Adaptimmune Therapeutics plc
13.2.11. Genelux Corporation
14. Research Methodology
15. Key Assumptions and Acronyms
  • Urigen Pharmaceuticals Inc.
  • GenVec.Inc
  • Oxford BioMedica
  • Vical
  • ANI Pharmaceuticals, Inc.
  • Genzyme Corporation
  • Novartis AG
  • Cell Medica
  • Cell Genesys Inc.
  • Adaptimmune Therapeutics plc
  • Genelux Corporation